A persistent assumption in pharma digital strategy holds that AI adoption in medicine is a generational divide — that younger physicians are driving the change while senior clinicians remain skeptical. New behavioral data from ZoomRx dismantles that assumption directly.
Between Q1 2025 and Q1 2026, ZoomRx's Passive Digital Tracker monitored real-world browsing behavior among a panel of US Hematologists and Oncologists. The finding is unambiguous: across nearly every years-of-practice band, more than half of physicians frequently use AI for clinical research. Over 75% use it at least sometimes.
AI adoption among Heme/Oncs nearly tripled in twelve months — rising from 17% in Q1 2025 to 46% in Q1 2026. Simultaneously, time share on medical AI platforms grew approximately 5.9x, climbing from under 2% to nearly 9% of all healthcare-related browsing.
These numbers represent observed behavior, not self-reported intent. Physicians were not asked how often they use AI — their digital behavior was passively captured in real time. The result is a dataset that reflects what physicians actually do, not what they believe they do.
The forward-looking attitudinal data reinforces the behavioral signal. Across all segments, physicians plan to increase their AI usage over the next twelve months — including 86% of frequent users, 63% of occasional users, and, remarkably, 67% of current non-users.
This trajectory is not dependent on any single cohort. It is distributed across experience levels, making it structurally durable. Pharma teams waiting for "the next generation" of physicians to drive AI adoption should note: that generation is already practicing.
Suggested Read: The Pharma Brand Website Isn't Obsolete. But Its Job Description Has Changed Permanently.
The universality of AI adoption carries a direct implication for pharmaceutical marketing: there is no physician segment for which AI-adjacent digital strategy can be safely deprioritized. If a Heme/Onc is evaluating your treatment — whether they graduated five years ago or thirty — there is a greater than 75% chance they are using AI at some point in that research process.
The question for pharma is no longer whether physicians are using AI. It is whether your brand is visible when they do.
The data summarized here is drawn from ZoomRx's Passive Digital Tracker — a longitudinal behavioral panel capturing real-world browsing activity among verified US Hematologists and Oncologists — and a complementary April 2026 Pulse Survey of 70 Heme/Onc physicians. ZoomRx Media Tracking is built to surface this kind of behavioral intelligence at the product and channel level, across digital, TV, and Med AI platforms. For the full cross-generational breakdown and its strategic implications, download the complete white paper below.